Entrada Therapeutics (TRDA)
Applies a cyclic-peptide delivery platform to exon-skipping therapies for Duchenne muscular dystrophy and myotonic dystrophy.
$6.39
vs last close−0.32 (−4.71%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 75.17% | 29.27M shares | |
|---|---|---|---|
| 130 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 22.87% | 8.90M shares | |
| 8 holders · as of Sep 9, 2026 | |||
| Strategic holders | 21.48% | 8.36M shares | |
| 3 holders · as of Aug 10, 2026 | |||
| Adds to | 119.52% | ||
38.94M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 119.52%; nothing is left for Other.
13F, as of Jun 30, 2026
130 holders · 29.27M shares · 29 new positions · 83 increased · 31 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 5.07M | 13.03% | 0 | Aug 14, 2026 |
| 5Am Venture Management, LLC | 4.06M | 10.42% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 2.58M | 6.63% | +224.5K | Aug 7, 2026 |
| Merck & Co., Inc. | 1.74M | 4.47% | +1.74Mnew | Aug 7, 2026 |
| Vanguard Capital Management LLC | 1.27M | 3.26% | +13.6K | Aug 13, 2026 |
| Bioimpact Capital LLC | 1.25M | 3.22% | +1.25Mnew | Aug 14, 2026 |
| TCG Crossover Management, LLC | 1.06M | 2.72% | −1.23M | Aug 14, 2026 |
| Wellington Management Group LLP | 954.4K | 2.45% | −80.4K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Kush Parmarincl. 5AM Partners V, LLC, 5AM Opportunities I, L.P. +4 more | 10.80% | 4.12M | 13D | Nov 18, 2025 |
| Todd Foleyincl. MPM Bioventures 2018 (B), L.P., MPM BioVentures 2018 GP LLC +10 more | 9.90% | 3.89M | 13D | Sep 10, 2026 |
| Roche Finance Ltd | 6.90% | 2.57M | 13G | Feb 14, 2025 |
| BlackRock, Inc. | 5.30% | 1.97M | 13G | Feb 4, 2025 |
| TCG Crossover GP I, LLC | 5.00% | 1.92M | 13G | Nov 25, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 9, 2026 | BioVentures 2014 L.P. MPM10 percent owner | Sale | 28,837 | $7.13 | 3,885,115 |
| Sep 8, 2026 | BioVentures 2014 L.P. MPM10 percent owner | Sale | 192,500 | $7.41 | 3,913,952 |
| Sep 4, 2026 | BioVentures 2014 L.P. MPM10 percent owner | Sale | 38,500 | $7.11 | 4,106,452 |
| Sep 9, 2026 | Bioventures 2018 L.p. Mpm10 percent owner | Sale | 28,837 | $7.13 | 3,885,115 |
| Sep 8, 2026 | Bioventures 2018 L.p. Mpm10 percent owner | Sale | 192,500 | $7.41 | 3,913,952 |
| Sep 4, 2026 | Bioventures 2018 L.p. Mpm10 percent owner | Sale | 38,500 | $7.11 | 4,106,452 |
| Sep 3, 2026 | BioVentures 2014 L.P. MPM10 percent owner | Sale | 32,263 | $7.17 | 4,144,952 |
| Sep 2, 2026 | BioVentures 2014 L.P. MPM10 percent owner | Sale | 25,131 | $7.19 | 4,177,215 |
| Sep 1, 2026 | BioVentures 2014 L.P. MPM10 percent owner | Sale | 29,088 | $7.06 | 4,202,346 |
| Sep 3, 2026 | Bioventures 2018 L.p. Mpm10 percent owner | Sale | 32,263 | $7.17 | 4,144,952 |
House and Senate disclosures
Not reported.